Aurobindo Pharma Limited announced on 28 May 2025 that Curateq Biologics Private Limited, its wholly-owned subsidiary, has incorporated a new wholly-owned subsidiary in the Netherlands named CuraTeQ Biologics B.V.
Incorporated on 28 May 2025, the new entity operates within the Biopharma Products industry.
The strategic objective behind this incorporation is to expand the Biopharma Products business in Europe.
The incorporation involved a 100% cash subscription to the share capital, with an initial investment of EURO 10,000, representing 10,000 shares of EURO 1.00 each.
CuraTeQ Biologics B.V. is a related party to Aurobindo Pharma Limited, being a wholly-owned subsidiary of its wholly-owned subsidiary. The promoters and promoter group of Aurobindo Pharma have no interest in this transaction.
No governmental or regulatory approvals were required for this incorporation.